拓扑替康联合顺铂治疗非小细胞肺癌的临床观察

Clinical observation of Topotecan combined Cisplatin in adranced non-small cell lung cancer

目的观察拓仆替康联合顺铂治疗晚期非小细胞肺癌的临床疗效及毒性反应。方法观察组使用拓扑替康联合顺铂治疗晚期非小细胞肺癌 2 9例。对照组 30例晚期非小细胞肺癌使用EP、CAP方案。结果观察组总有效率 5 5 17% ,对照组总有效率 33 33% ,P <0 0 5 ,差异有显著意义 ,但观察组血液系统毒性反应程度及发生率均高于对照组 ,P >0 0 5 ,差异无显著意义 ,两组非血液性毒性反应相似 ,肝、肾功能基本正常。结论观察组疗效确切 ,毒性反应可以耐受 ,说明拓扑替康联合顺铂治疗晚期非小细胞肺癌较好的疗效 。

Objective To evaluate the effects and safely of topotecan combined cisplatin in advanced non-small cell lung cancer (NSCLC). Methods 59 cases of advanced NSCLC were randomly divided into observed group and controled group. 29 cases of ovserved group were treated with topotecan and cisplatin. 30 cases of control group were treated with CTX+ADM+DDP (CAP) or VP-16+DDP (EP). Results The response rate of observed group and controled group were 55.17% (16/29) and 33.33% (10/30) respectively ( P <0.05).Hematologic toxicity observed group were higher than control group ( P >0.05). Conclusion Topotecan and Cisplatin can be combined safely. Response rate compare favoratly for NSCLC.